Clinical trial
An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors
NCT05091346 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors
- Lead sponsor
- Eisai Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 27, 2021
- Completion date
- October 15, 2024
- Enrollment
- 89 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.